Positron Emission Tomography

68Gallium-DOTATATE is a somatostatin analog PET/CT tracer that binds to the somatostatin receptors which are over expressed in neuroendocrine tumors.

The most sensitive exam for neuroendocrine tumors

Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms, arising from endocrine cells within glands (adrenal medulla, pituitary, parathyroid) or from endocrine islets in the thyroid, pancreas, respiratory and gastrointestinal tracts.

  • Most common tumors are:
    • Gastrointestinal NETs as carcinoids and gastrinoma
    • Pancreatic NETs as insulinoma, glucagonoma, VIPoma, and gastrinoma
    • Bronchopulmonary carcinoids
    • Sympatho-adrenal system tumors as pheochromocytoma, paraganglioma, neuroblastoma and ganglioneuroma
    • Medullary thyroid carcinoma
  • Other non-NETs showing overexpression of somatostatin receptors as meningiomas, medulloblastomas, pituitary tumors, supratentorial primitive neuroectodermal tumors, and hemangioblastomas.
  • Primary staging of a known neuroendocrine tumor before surgical and/or therapeutic planning.
  • Localization of the primary tumor in case of metastatic neuroendocrine deposits.
  • Determine somatostatin receptor (SST) status as patients with SST receptor-positive tumors are more likely to respond to Octreotide or radionuclide therapy with 177Lutetium.
  • Detection of NETs in patients with multiple endocrine neoplasia (MEN) of various types.
  • Following up of known NETs patients to assess response to therapy.
  • Used in brain tumors that show overexpression of somatostatin receptors, especially in post-operative assessment.


Call 19773 Now or Fill The Contact Form